Pulmonx Stock

Pulmonx EBITDA per Employee

The EBITDA per Employee of Pulmonx (LUNG) as of Aug 11, 2026 is -315,664.71 USD. In the previous year, EBITDA per Employee was -339,435.29 USD — a change of -7.00% (higher).

EBITDA per Employee

-315,664.71USD

YoY

-7.00%

Last updated:

EBITDA per Employee of Pulmonx is 2026 -315,664.71 USD. EBITDA per Employee of Pulmonx was 2025 -339,435.29 USD. It decreases by -7.00% higher compared to the previous year.
Access this data via the Eulerpool API

Pulmonx Stock analysis

What does Pulmonx do? Pulmonx Corp is an innovative medical technology company based in the USA and Europe. The company specializes in the development of non-invasive solutions for the treatment of lung diseases. Pulmonx was founded in 1997 and has since introduced numerous groundbreaking technologies to the market that improve the quality of life for patients with chronic lung diseases. Pulmonx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pulmonx stock

EBITDA per Employee of Pulmonx is -315,664.71 USD in 2026.

EBITDA per Employee of Pulmonx changed from -339,435.29 USD to -315,664.71 USD, representing a -7.00% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Pulmonx since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Pulmonx historically and in real time.

Access this data via the Eulerpool API

Workforce — Pulmonx

All Key Metrics — Pulmonx